Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
Public ClinicalTrials.gov record NCT00048581. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 in Subjects With Active Rheumatoid Arthritis on Background Disease Modifying Anti-Rheumatic Drugs (DMARDS) Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this clinical research study is to determine whether abatacept treatment on a background of Disease Modifying Antirheumatic Drugs (DMARDs) will relieve the symptoms of rheumatoid arthritis (RA) in participants who are currently receiving anti-tumor necrosis factor (TNF) therapy for at least 3 months and are not responding or have taken anti-TNF therapy in the last 3 months and did not respond. The safety of treatment with abatacept will also be evaluated. This study also has a 4.5-year long-term extension beginning 6 months after the start of the study.
Study identification
- NCT ID
- NCT00048581
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 738 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2002 (Type not available)
- Primary completion
- Sep 2009 (Actual)
- Completion
- Sep 2009 (Actual)
- Last update posted
- Nov 21, 2011
2002 – 2009
United States locations
- U.S. sites
- 42
- U.S. states
- 24
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Birmingham | Alabama | — | — |
| Local Institution | Mobile | Alabama | — | — |
| Local Institution | Paradise Valley | Arizona | — | — |
| Local Institution | La Jolla | California | — | — |
| Local Institution | Long Beach | California | — | — |
| Local Institution | Palo Alto | California | — | — |
| Local Institution | Rancho Mirage | California | — | — |
| Local Institution | Denver | Colorado | — | — |
| Local Institution | Englewood | Colorado | — | — |
| Local Institution | Bridgeport | Connecticut | — | — |
| Local Institution | Hamden | Connecticut | — | — |
| Local Institution | Clearwater | Florida | — | — |
| Local Institution | Fort Lauderdale | Florida | — | — |
| Local Institution | Largo | Florida | — | — |
| Local Institution | Palm Harbor | Florida | — | — |
| Local Institution | Tampa | Florida | — | — |
| Local Institution | Rome | Georgia | — | — |
| Local Institution | Indianapolis | Indiana | — | — |
| Local Institution | Wichita | Kansas | — | — |
| Local Institution | New Orleans | Louisiana | — | — |
| Local Institution | Boston | Massachusetts | — | — |
| Local Institution | Springfield | Massachusetts | — | — |
| Local Institution | Lincoln | Nebraska | — | — |
| Local Institution | New Brunswick | New Jersey | — | — |
| Local Institution | Albany | New York | — | — |
| Local Institution | Syracuse | New York | — | — |
| Local Institution | Charlotte | North Carolina | — | — |
| Local Institution | Hickory | North Carolina | — | — |
| Local Institution | Bismarck | North Dakota | — | — |
| Local Institution | Cincinnati | Ohio | — | — |
| Local Institution | Oklahoma City | Oklahoma | — | — |
| Local Institution | Eugene | Oregon | — | — |
| Local Institution | Portland | Oregon | — | — |
| Local Institution | Duncansville | Pennsylvania | — | — |
| Local Institution | Norristown | Pennsylvania | — | — |
| Local Institution | Sellersville | Pennsylvania | — | — |
| Local Institution | Willow Grove | Pennsylvania | — | — |
| Local Institution | Charleston | South Carolina | — | — |
| Local Institution | Austin | Texas | — | — |
| Local Institution | Dallas | Texas | — | — |
| Local Institution | Vancouver | Washington | — | — |
| Local Institution | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00048581, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 21, 2011 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00048581 live on ClinicalTrials.gov.